Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H23NO2.ClH |
| Molecular Weight | 297.82 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1CCCCN1CCCOC(=O)C2=CC=CC=C2
InChI
InChIKey=ZXSGQNYQJIUMQN-UHFFFAOYSA-N
InChI=1S/C16H23NO2.ClH/c1-14-8-5-6-11-17(14)12-7-13-19-16(18)15-9-3-2-4-10-15;/h2-4,9-10,14H,5-8,11-13H2,1H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H23NO2 |
| Molecular Weight | 261.3593 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/18138121Curator's Comment: Description was created using several sources including:
http://www.annualreviews.org/doi/abs/10.1146/annurev.pa.09.040169.002443?journalCode=pharmtox.1; http://www.ncbi.nlm.nih.gov/pubmed/15402120; http://www.ncbi.nlm.nih.gov/pubmed/18149171; http://www.ncbi.nlm.nih.gov/pubmed/7635175; http://purl.bioontology.org/ontology/NDDF/003425; http://www.accessdata.fda.gov/scripts/animaldrugsatfda/details.cfm?dn=040-123
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm467373.pdf;
https://books.google.com/books?id=79BGAQAAMAAJ&pg=PA263&lpg=PA263&dq=METYCAINE+was+manufactured&source=bl&ots=-PQVR0IZgE&sig=9DfpIP-V1qufWzn5gmpEzdVfYVY&hl=en&sa=X&ved=0ahUKEwjr-qjk2rHLAhUJ8CYKHTG0DdkQ6AEILzAE#v=onepage&q=METYCAINE%20was%20manufactured&f=false
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18138121
Curator's Comment: Description was created using several sources including:
http://www.annualreviews.org/doi/abs/10.1146/annurev.pa.09.040169.002443?journalCode=pharmtox.1; http://www.ncbi.nlm.nih.gov/pubmed/15402120; http://www.ncbi.nlm.nih.gov/pubmed/18149171; http://www.ncbi.nlm.nih.gov/pubmed/7635175; http://purl.bioontology.org/ontology/NDDF/003425; http://www.accessdata.fda.gov/scripts/animaldrugsatfda/details.cfm?dn=040-123
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm467373.pdf;
https://books.google.com/books?id=79BGAQAAMAAJ&pg=PA263&lpg=PA263&dq=METYCAINE+was+manufactured&source=bl&ots=-PQVR0IZgE&sig=9DfpIP-V1qufWzn5gmpEzdVfYVY&hl=en&sa=X&ved=0ahUKEwjr-qjk2rHLAhUJ8CYKHTG0DdkQ6AEILzAE#v=onepage&q=METYCAINE%20was%20manufactured&f=false
Piperocaine (Metycaine) is a local anesthetic drug. It is an ester and primarily is a sodium channel blocker. Piperocaine can partially inhibit dopamine. It is known as a alpha-1-proteinase inhibitor. Used in the form of its hydrochloride as a local or spinal anesthetic and in dental anesthesia. Can cause toxic reactions. Piperocaine Hydrochloride is in the list of Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, FDA Act. Piperocaine hydrochloride is a small, white odorless crystals or a white crystalline powder, stable in air, freely soluble in water, alcohol and chloroform.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3350224 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1922660 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Metycaine Hydrochloride Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
60 mg single, dental Recommended |
unhealthy, 10-90 |
Other AEs: Tremor, Tremor... Other AEs: Tremor (slight, 28.1%) Sources: Tremor (moderate, 3.5%) Sweating (slight, 17.5%) Sweating (moderate, 1.8%) Nervousness (slight, 29.8%) Nervousness (moderate, 5.3%) Nervousness (extreme, 8.8%) Faintness (5.3%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Faintness | 5.3% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
| Nervousness | extreme, 8.8% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
| Sweating | moderate, 1.8% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
| Tremor | moderate, 3.5% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
| Nervousness | moderate, 5.3% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
| Sweating | slight, 17.5% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
| Tremor | slight, 28.1% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
| Nervousness | slight, 29.8% | 60 mg single, dental Recommended |
unhealthy, 10-90 |
Sample Use Guides
For continuous caudal analgesia in obstetrics initial dose of 30 ml of 1 and 1.5 % metycaine produced analgesia as high as the line midway between the pubis and the umbilicus and relieved the pains of labor.
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7635175
At a maximum concentration of 100 uM, the ester containing local anesthetics procaine, tetracaine, piperocaine and the amide containing local anesthetic dibucaine and bupivacaine partially inhibited dopamine uptake by 47-70%
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:43:02 GMT 2025
by
admin
on
Mon Mar 31 20:43:02 GMT 2025
|
| Record UNII |
Q2RH0XR1MB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL127865
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
100000138600
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
m8857
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID2046709
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
10781
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
Q2RH0XR1MB
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
C90655
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
533-28-8
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
SUB78164
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY | |||
|
C023039
Created by
admin on Mon Mar 31 20:43:02 GMT 2025 , Edited by admin on Mon Mar 31 20:43:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |